Effect of high dose SGLT-2 inhibitor on fatty liver
Not Applicable
- Conditions
- type2 diabetes/fatty liver
- Registration Number
- JPRN-UMIN000047270
- Lead Sponsor
- Konuma Internal medicine Gastroenterology Clinic directer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have completed less than 6 months of high-dose SGLT-2 inhibitor therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare AST, ALT, FIB-4 index, and NAFLD fibrosis score (NFS) before and after treatment in patients receiving high dose SGLT-2 inhibitor for at least 6 months
- Secondary Outcome Measures
Name Time Method